WideCells Group


CellPlan - Revenue with launch of first UK insurance product for stem cell treat

News Release | NewsRoom

WideCells Group PLC (‘WideCells Group’ or ‘the Group’)

CellPlan - Revenue with launch of first UK insurance product for stem cell treatment

WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground breaking insurance for stem cell treatment, is delighted to announce that its 100% owned subsidiary, CellPlan Limited (‘CellPlan’), has launched a first-of-its-kind stem cell healthcare insurance in the UK with CellPlan now available for purchase by customers of Biovault Technical Ltd ('Biovault'), the UK's largest private human tissue storage facility. Additionally, the Company’s e-commerce platform, which allows the Group to sell CellPlan directly to families, will be made live during the next few weeks.  This marks an inflection point for the Group, with the generation of maiden revenues from CellPlan expected imminently.

CellPlan enables individuals, who have gone through the expense of storing stem cells from umbilical cords, to cover the high-cost of stem cell treatment through an affordable insurance product, which provides cover for up to €1 million of medical, travel and accommodation expenses.  Customers will also have access to an expert second medical opinion and a global concierge service if treatment is carried out abroad.

Biovault is a member of the elite CellPlan Excel Programme, meaning that it adheres to the Group’s stringent quality standards, and currently stores more than 25,000 cord blood samples.  The insurance product will be sold to all new and existing Biovault customers.  For further details on the agreement entered into between Biovault and CellPlan, please see the announcement dated 9 January 2017.  Notably, effective from today, every new Biovault customer will receive CellPlan for a 12 month period, the cost of which will be covered by Biovault as part of a Biovault package to new storage customers.  This campaign alone has the potential to create a solid and recurring stream of revenue for the Group during 2017 and beyond due to the historically very high rate of clients who renew after the initial 12-month term.  

Biovault is also initiating a defined marketing strategy to educate the market on the key differentiators of its storage offering and the CellPlan insurance product, which the Board believes will ensure strong uptake of CellPlan amongst existing Biovault clients.  Existing Biovault customers and families that have stored stem cells in facilities currently not members of the CellPlan Excel Member Programme but which meet standards adhered to by the programme (the ‘Extended Provider Network’) will be able to purchase CellPlan via the Company’s e-commerce platform in the next few weeks.  

CellPlan’s agreement with Biovault can be used as a benchmark for future agreements with other cord blood storage facilities.  

The average price of the CellPlan product is £170 per annum and under its reseller model CellPlan will generate an average of £50 balance from each sale, after disbursements, commissions and reinsurance costs.   CellPlan will take a greater share of the margin for sales generated from the Extended Provider Network given that no commission payment will be required. 

To mark and celebrate today’s launch, CellPlan will be hosting an event at its offices on Friday 14 July 2017 for local press, partners and current and potential clients.  This will also be promoted digitally.

WideCells Group CEO, João Andrade, said, “With first sales expected imminently, this is a milestone for CellPlan and the Group as a whole.  We are leveraging Biovault's register of over 25,000 samples to generate sales of our innovatively complete stem cell insurance product and are delighted that all new customers of the UK’s leading cord blood storage facility will become customers of CellPlan.  CellPlan is genuinely making stem cell treatment accessible and affordable to families that have gone through the expense of storing stem cells from umbilical cord blood and who most likely do not have the financial safety net to cover the costs to use their stem cells, therefore we believe that uptake will be equally strong amongst Biovault’s existing client base and our Extended Provider Network.

“Crucially, we expect our agreement with Biovault will provide a framework for future agreements that are in our pipeline.  In line with this, we are pleased to report that we are already experiencing demand from other members of our Excel Membership Programme for our insurance product and accordingly believe we are poised to generate additional recurring revenues from CellPlan in the near future.  We look forward to reporting on these sales initiatives in the near future.  This is the start of our future, which we believe will see us become the leading stem cell support services company globally.”

**ENDS**

For further information, please visit the Company’s website www.widecellsgroup.com, follow us on Twitter @WideCells_Group or contact:

WideCells Group

CEO – João Andrade

Tel:  +351 919 033 171

Smaller Company Capital Ltd

Broker – Jeremy Woodgate & Rupert Williams

Tel: +44 (0) 20 3651 2912

Shard Capital Partners LLP

Broker – Damon Heath & Erik Woolgar

Tel: +44 (0) 207 186 9950

St Brides Partners Ltd

PR – Charlotte Page & Olivia Vita

Tel: +44 (0) 20 7236 1177

Notes to Editors

WideCells Group PLC is building an integrated stem cell services company, focused on making stem cell treatments accessible and affordable.  In June 2017, the Group was ranked as the 21st most disruptive company globally by DISRUPT 100, an annual index celebrating the businesses with the most potential to influence, change or create new global markets.

With this in mind, it has created three divisions:

  • CellPlan: the world’s first stem cell healthcare insurance plan with financial cover for medical treatment, travel and accommodation expenses and concierge service to manage the treatment process
  • WideCells: the Institute of Stem Cell Technology has been established and is based in the University of Manchester Innovation Centre to focus on stem cell research and regenerative medicine. WideCells also has international cryogenics divisions specialising in stem cell storage.
  • WideAcademy: developing an education and training division to promote awareness of the benefits of stem cell storage across the global general practice community.

The Group has built an experienced senior management team that has been integral to the development of its growth and business to date.

Stem Cell Fast Facts:

  • Cord blood (which is taken from the umbilical cord) provides the most effective source of stem cells for families due to it being simple, safe and painless to collect relative to other sources of stem cells such as bone marrow – WideCells will focus on promoting the collection and storage of this.
  • Since 2005, there has been a 300% increase in the number of illnesses that can be treated using stem cells
  • 82 illnesses can currently be treated using stem cell procedures
  • Despite initial storage often costing no more than a few £thousand, actual treatment can cost in the £hundreds of thousands

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 (MAR).

Sources

WideCells Group PLC